Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.
| Title: | Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer. |
|---|---|
| Authors: | Sachdeva M; National University Cancer Institute Singapore, Singapore Singapore.; Tan DSP; National University Cancer Institute Singapore, Singapore Singapore. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Apr 23. Date of Electronic Publication: 2026 Apr 23. |
| Publication Model: | Ahead of Print |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Denville, NJ : American Association for Cancer Research, c1995- |
| Abstract: | The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer (PSROC) previously treated with PARPi. With a 68% 6-month progression-free survival (PFS) rate, this combination may synergistically be able to overcome acquired PARPi resistance, particularly in patients with favorable platinum sensitivity. |
| Entry Date(s): | Date Created: 20260423 Latest Revision: 20260423 |
| Update Code: | 20260423 |
| DOI: | 10.1158/1078-0432.CCR-26-0534 |
| PMID: | 42024147 |
| Database: | MEDLINE |
Journal Article